CTSC and COVID-19: Brensocatib (also called INS1007 or AZD7986), a DPP1 inhibitor, was found to reduce NE activity in healthy humans (Palmér et al., 2018) and is now in clinical trials for bronchiectasis (NCT03218917) and COVID-19 (EU clinical trial number EudraCT 2020-001643-13).